US Ophthalmology Association Warns Against Untested Avastin Alternatives
Discourages Using Pfizer’s Zirabev and Amgen’s Mvasi Biosimilars
The American Academy of Ophthalmology has criticized healthcare insurers for pushing bevacizumab biosimilar alternatives to Avastin, like Pfizer’s Zirabev and Amgen’s Mvasi, that have not been subjected to clinical trials in eye disease or testing for retinal toxicity.
